Search

Pfizer

Открыт

СекторЗдравоохранение

27.79 0.04

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

27.57

Макс.

27.94

Ключевые показатели

By Trading Economics

Доход

-2.9B

-238M

Продажи

583M

15B

P/E

Средняя по отрасли

37.434

56.597

Прибыль на акцию

0.77

Дивидендная доходность

5.97

Рентабельность продаж

-1.583

Сотрудники

75,000

EBITDA

-3.8B

1.2B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+2.41% upside

Дивиденды

By Acuity

Дивидендная доходность

Средняя по отрасли

5.97%

2.18%

Следующий отчет о доходах

3 нояб. 2026 г.

Следующая эксдивидендная дата

6 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

19B

162B

Предыдущая цена открытия

27.75

Предыдущая цена закрытия

27.79

Новостные настроения

By Acuity

48%

52%

127 / 339 Рейтинг в Healthcare

Pfizer График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

8 сент. 2026 г., 20:08 UTC

News
Social Media

Pfizer shares are lower as the company announces a webcast featuring CEO Albert Bourla at the Morgan Stanley Healthcare Conference scheduled for September 2026.

4 сент. 2026 г., 23:05 UTC

Pfizer Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid mixed economic signals affecting market sentiment.

3 сент. 2026 г., 23:01 UTC

Pfizer Inc. shares are lower in after-market hours, following a weak trading session and amid broader market softness from recent economic data on jobless claims.

2 сент. 2026 г., 23:06 UTC

Pfizer Inc. shares are lower in after-market hours, amid a weaker ADP payrolls report signaling potential labor market weakness affecting future Federal Reserve policy.

1 сент. 2026 г., 20:09 UTC

News

Pfizer Inc shares reached a 22-month high of $28.86 today, driven by a significant upward trend in the Pharmaceuticals sub-sector amid overall market gains.

31 авг. 2026 г., 23:06 UTC

Pfizer Inc shares rose in after-hours trading, holding above the 20-day moving average and near the upper end of their one-month range.

28 авг. 2026 г., 23:01 UTC

Pfizer Inc. shares are lower in after-market trading, continuing a trend from the previous three sessions. No specific news was identified to explain the decline.

27 авг. 2026 г., 23:02 UTC

Social Media
News

Pfizer and BioNTech received FDA approval for their XFG-adapted COVID-19 vaccine, COMIRNATY XFG, boosting shares in after-market trading.

26 авг. 2026 г., 23:06 UTC

Pfizer Inc shares are lower in after-market hours amid notable volatility. Broader market weakness and a stronger U.S. Dollar Index contributed to the decline.

25 авг. 2026 г., 23:06 UTC

Pfizer Inc. shares are lower in after-market trading, reflecting weaker sentiment amid broader market declines linked to falling crude oil prices.

24 авг. 2026 г., 19:36 UTC

Pfizer Inc. shares are lower today, continuing a decline since Friday's close. The stock remains above its 20-day moving average.

21 авг. 2026 г., 23:01 UTC

Pfizer Inc shares are lower in after-market trading, reflecting a downward trend amid broader market volatility related to inflation and government debt concerns.

20 авг. 2026 г., 19:41 UTC

Pfizer Inc's shares are lower today amid a broader downturn in the Pharmaceuticals sub-sector, marking a shift from recent gains.

19 авг. 2026 г., 23:51 UTC

Pfizer Inc shares are lower in after-market hours, reversing gains from three consecutive sessions. No specific news was identified to explain the price action.

18 авг. 2026 г., 19:16 UTC

Social Media
Event

Pfizer reported second-quarter adjusted EPS of $0.77, exceeding estimates, and raised its sales outlook for fiscal year 2026, with shares trading higher.

17 авг. 2026 г., 23:36 UTC

Event

Pfizer Inc shares are lower in after-market hours following the announcement of Xtandi's new indication for prostate cancer treatment. The broader market also declined.

14 авг. 2026 г., 23:51 UTC

Pfizer Inc. shares are higher in after-market hours amid broader economic concerns following a reported decline in U.S. retail sales for July.

13 авг. 2026 г., 23:16 UTC

Pfizer Inc shares are lower in after-market hours following a decline from earlier gains. No specific news was identified to explain the movement.

12 авг. 2026 г., 23:02 UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

11 авг. 2026 г., 19:26 UTC

News

Pfizer Inc. shares are lower amid a $44 million settlement over its Chantix drug, which allegedly contained a cancer-linked substance.

10 авг. 2026 г., 23:01 UTC

Pfizer Inc. shares are lower in after-market hours, continuing a decline since Monday's close amid rising Treasury yields and inflation concerns.

8 авг. 2026 г., 00:02 UTC

Pfizer Inc shares are lower in after-market hours with no specific news identified. Broader market concerns about interest rate hikes continue to influence sentiment.

7 авг. 2026 г., 23:01 UTC

Pfizer Inc shares are lower in after-market hours, reaching a session low earlier. No specific news was identified to explain the decline.

6 авг. 2026 г., 23:51 UTC

Pfizer Inc shares are lower in after-market hours. The decline follows increased crude oil prices and a strengthening U.S. dollar, contributing to market volatility.

5 авг. 2026 г., 23:02 UTC

Pfizer Inc shares are modestly higher in after-market hours, reaching a session high before pulling back slightly. No specific news was identified for the movement.

4 авг. 2026 г., 23:21 UTC

Pfizer Inc shares are lower in after-market hours, with no specific news identified for the decline. Broader market sentiment remains positive amid falling crude oil prices.

3 авг. 2026 г., 23:46 UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

31 июл. 2026 г., 23:06 UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

30 июл. 2026 г., 23:26 UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

29 июл. 2026 г., 23:16 UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

Сравнение c конкурентами

Изменение цены

Pfizer Прогноз

Целевая цена

By TipRanks

2.41% рост

Прогноз на 12 месяцев

Средняя 28.46 USD  2.41%

Максимум 35.75 USD

Минимум 25 USD

Основано на мнении 21 аналитиков Wall Street, спрогнозировавших целевые цены для Pfizer  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

21 ratings

7

Покупка

13

Удержание

1

Продажа

Настроения

By Acuity

127 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat